Adalimumab-ryvk Kit
Product Images NDC 51759-360

Product Visual Gallery

This gallery contains 53 technical images submitted to the FDA as part of the official labeling for Adalimumab-ryvk (NDC 51759-360). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Avt02 Unbranded 1)

A line graph comparing the percent of ACR20 responders over time (weeks) between two groups: one receiving 40 mg of medication every other week and a placebo group. The x-axis displays time in weeks up to 48, and the y-axis shows the percent ACR20 responders ranging from 0 to 70 percent. The treatment group shows a higher and sustained response compared to placebo over time.*

FDA Label Image

1 (Avt02 Unbranded 10)

An instructional illustration labeled Figure E showing a person washing hands under running water from a faucet. The image depicts proper hand hygiene technique relevant to medication administration or handling.*

FDA Label Image

1 (Avt02 Unbranded 11)

An instructional illustration showing a frontal view of a human torso and upper legs, with orange highlighted areas around the abdomen and upper outer thighs, indicating recommended injection sites for medication administration.*

FDA Label Image

1 (Avt02 Unbranded 12)

Illustration labeled Figure G showing a hand holding a cotton ball, applying it on a surface with circular arrows indicating motion for cleansing or wiping.*

FDA Label Image

Figure H (Avt02 Unbranded 13)

An illustration showing an Adalimumab-ryvk injection pen with a zoomed inset highlighting a fluid-filled indicator window containing bubbles. The label on the pen indicates a 40 mg/0.4 mL dose. This figure likely depicts a detail related to the injection device included in the kit by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Figure I (Avt02 Unbranded 14)

An instructional illustration showing a hand holding an Adalimumab-ryvk injection device labeled with "40 mg/0.4 mL." The illustration depicts the step of pressing the device down onto a square adhesive patch held by another hand, indicating application of the injection site preparation or securing of the device.*

FDA Label Image

Figure J (Avt02 Unbranded 15)

An instructional illustration showing a person holding an Adalimumab-ryvk injection device at a 90-degree angle to the skin, demonstrating the correct injection technique. The image focuses on hand positioning and angle for administering the injection as part of the Adalimumab-ryvk kit by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Figure K & Figure L (Avt02 Unbranded 16)

An instructional illustration showing two steps labeled Figure K and Figure L for using the Adalimumab-ryvk kit. Figure K depicts pressing the device with a downward arrow and the text '1st Click' near the indicator window, accompanied by a timer showing to wait up to 10 seconds. Figure L shows pressing again with the text '2nd Click' by the indicator window, demonstrating the second step in using the kit.*

FDA Label Image

Figure M (Avt02 Unbranded 17)

An instructional illustration showing a hand holding a medication pen injector labeled with a dose indicator, and a separate image demonstrating a finger pressing against skin, accompanied by the text "Figure M." The images depict steps for using the pen injector device.*

FDA Label Image

Figure N (Avt02 Unbranded 18)

An instructional illustration showing a hand discarding a used prefilled injection device or pen into a red sharps disposal container with a yellow lid. The image demonstrates safe disposal of medical sharps or injection materials.*

FDA Label Image

1 (Avt02 Unbranded 19)

FDA Label Image

1 (Avt02 Unbranded 2)

A line graph comparing the percentage of ASAS 20 response over time in weeks between two groups: one receiving Adalimumab (N=208) and a placebo group (N=107). The Adalimumab group shows a higher and more sustained response compared to the placebo group across a 24-week period.*

FDA Label Image

80 mg Ai (Avt02 Unbranded 20)

A labeled illustration of a kit component showing a clear cap, orange needle sleeve, an inspection window, and a gray body grip area. The diagram highlights the parts of a pen-like device used for drug administration.*

FDA Label Image

1 (Avt02 Unbranded 21)

An instructional diagram labeled Figure A showing a hand inserting a rectangular card or object into a slot, possibly depicting a step in using the Adalimumab-ryvk kit.*

FDA Label Image

1 (Avt02 Unbranded 22)

An instructional diagram labeled Figure B, showing a circular clock face with a red shaded area covering the right half, and the text "15 to 30 minutes" centered inside the clock face. The illustration likely indicates a time duration related to the product use or process.*

FDA Label Image

Figure C (Avt02 Unbranded 23)

An illustration labeled Figure C showing a kit containing a syringe or injection device. The syringe has a white and orange body with a gray and white textured grip area. The image indicates areas for expiration date (EXP), lot number, and a barcode on the syringe and packaging components. The kit is associated with Adalimumab-ryvk by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Figure D (Avt02 Unbranded 24)

Illustration showing four items from a medication administration kit: a prefilled injection device (possibly a pen), an alcohol swab packet, a cotton ball or gauze pad, and a red sharps disposal container. The image is labeled as Figure D, suggesting instructions or steps for use.*

FDA Label Image

1 (Avt02 Unbranded 25)

An instructional illustration labeled Figure E showing two hands under running water from a faucet, demonstrating hand washing with soap.*

FDA Label Image

1 (Avt02 Unbranded 26)

An instructional diagram showing a front view of a human torso and upper legs with three areas highlighted in orange as recommended injection sites: the abdomen around the navel and the front parts of both thighs. The image is labeled 'Figure F.'*

FDA Label Image

1 (Avt02 Unbranded 27)

An illustration labeled Figure G showing a hand holding a tissue or cloth and making a circular wiping motion on a surface, indicated by curved arrows around the hand. This instructional figure likely depicts cleaning or wiping technique.*

FDA Label Image

Figure H (Avt02 Unbranded 28)

An illustration showing a prefilled injection device, likely part of a kit, with a close-up inset highlighting the liquid window revealing the medication inside. The figure is labeled as 'Figure H' underneath the diagram.*

FDA Label Image

Figure I (Avt02 Unbranded 29)

An instructional diagram illustrating a hand holding a pen device or injector with the cap being removed and a separate hand holding a small alcohol swab pad below. The image is labeled as Figure I, showing the step of preparing the injection site by cleaning it with the swab before use.*

FDA Label Image

1 (Avt02 Unbranded 3)

This chart depicts treatment failure rates over time (in months) comparing placebo and adalimumab treatment groups. The vertical axis shows the percentage of treatment failure, while the horizontal axis represents time in months up to 20 months. The graph includes curves for placebo and adalimumab, showing lower treatment failure rates in the adalimumab group across the time course.*

FDA Label Image

Figure J (Avt02 Unbranded 30)

An instructional illustration showing the application of a medication kit. One hand holds a pen-like injector device at a 90-degree angle to the skin on the other hand, which is prepared for injection. The image is labeled as Figure J, demonstrating proper technique for using an injection device, likely related to Adalimumab-ryvk.*

FDA Label Image

Figures K & L (Avt02 Unbranded 31)

Instructional illustration showing the steps to use the Adalimumab-ryvk injection kit. The first step is to press the device on the skin until the first click, then wait up to 15 seconds. The second step is to wait for the second click, indicating injection completion, while holding the device in place on the skin.*

FDA Label Image

Figure M (Avt02 Unbranded 32)

An instructional illustration showing a hand holding a pen-type injector device, with an arrow pointing upward indicating the direction to remove or hold the device. Below, another hand is shown pinching the skin, demonstrating how to prepare the injection site. The figure is labeled "Figure M."*

FDA Label Image

Figure N (Avt02 Unbranded 33)

An instructional illustration showing a hand disposing of a used prefilled injection device into a red sharps container with a yellow lid, labeled as Figure N. This diagram likely demonstrates proper disposal of the Adalimumab-ryvk injection kit components.*

FDA Label Image

1 (Avt02 Unbranded 34)

FDA Label Image

Parts Pfs (Avt02 Unbranded 35)

An instructional illustration of a syringe labeled with parts including the Needle Cover, Syringe Body, Finger Grip, and Plunger. The diagram visually identifies the main components of the syringe device for the Adalimumab-ryvk product kit by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

A (Avt02 Unbranded 36)

An instructional diagram labeled Figure A showing a hand placing a rectangular object into a refrigerator compartment, illustrating proper storage or handling steps.*

FDA Label Image

B (Avt02 Unbranded 37)

An instructional illustration resembling a clock face highlighting a 15 to 30-minute interval in red. The text "15 to 30 minutes" is centered within the clock, with "Figure B" labeled underneath, indicating a time-related step or waiting period in a procedure.*

FDA Label Image

C (Avt02 Unbranded 38)

An instructional illustration showing a hand holding an Adalimumab-ryvk prefilled syringe, indicating proper eye-level viewing of the expiration date printed on the syringe barrel.*

FDA Label Image

D (Avt02 Unbranded 39)

An illustration showing three items commonly included in a medication administration kit: a sealed alcohol swab packet labeled "Alcohol swab," a cotton ball, and a red sharps disposal container with a yellow lid and an oval opening at the top.*

FDA Label Image

1 (Avt02 Unbranded 4)

A line graph depicting treatment failure rates (%) over time (months) for treatment with adalimumab compared to placebo. The x-axis shows time in months from 0 to 20, and the y-axis shows treatment failure rate from 0% to 100%. Lines represent failure rates for adalimumab and placebo groups, with patient number data points noted below the x-axis.*

FDA Label Image

E (Avt02 Unbranded 40)

An instructional illustration showing hands being washed under running water from a faucet with soap lather, emphasizing hand hygiene.*

FDA Label Image

F (Avt02 Unbranded 41)

An instructional illustration shows appropriate injection sites for Adalimumab-ryvk on a human body. Highlighted areas include the abdomen around the navel and the front of both thighs. A circular inset demonstrates a hand cleaning the skin with a swab using circular motions before injection.*

FDA Label Image

G (Avt02 Unbranded 42)

This illustration shows hands demonstrating the removal of a protective cap from a syringe needle, an instructional image likely related to the preparation of the Adalimumab-ryvk kit for injection.*

FDA Label Image

H (Avt02 Unbranded 43)

An illustration showing proper technique for subcutaneous injection, with one hand pinching skin on an arm or abdomen and the other hand holding a syringe poised to insert the needle at an angle. The image demonstrates steps for administering an injection in a medical or instructional context.*

FDA Label Image

I (Avt02 Unbranded 44)

An instructional diagram showing how to inject using Adalimumab-ryvk kit. It depicts two methods of injection: one on the abdomen and another on the thigh, both illustrating holding the syringe at a 45-degree angle during administration.*

FDA Label Image

J (Avt02 Unbranded 45)

An instructional illustration showing a hand holding a syringe-like device positioned for subcutaneous injection into the skin. An arrow points downward indicating the direction to insert or press the injection device against the skin. The illustration is likely part of usage instructions for the Adalimumab-ryvk kit.*

FDA Label Image

K (Avt02 Unbranded 46)

Illustration showing a hand holding a syringe used for subcutaneous injection, with an arrow indicating the direction to administer the injection into the skin. This image is related to the administration of Adalimumab-ryvk, a prescription drug kit by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

L (Avt02 Unbranded 47)

An instructional illustration showing a hand disposing of a syringe into a red sharps container with a yellow lid. The image depicts the proper method of safely discarding a syringe after use.*

FDA Label Image

Calendar (Avt02 Unbranded 48)

FDA Label Image

80 mg Ai Carton (Avt02 Unbranded 49)

Packaging label for Simlandi (adalimumab-ryvk) Injection 80 mg/0.8 mL, a single-dose autoinjector for subcutaneous use. The label includes the brand and generic names, dosage strength, administration method, and contents of the carton. It is labeled by Teva Pharmaceuticals USA, Inc. and features the NDC 51759-274-17. The package includes one dose tray, alcohol prep, guidance materials, and prescribing information.*

FDA Label Image

Ai 40 mg (Avt02 Unbranded 5)

An instructional diagram of an Adalimumab-ryvk injection pen kit from Teva Pharmaceuticals USA, Inc. The illustrated pen is labeled with parts including a clear cap, orange needle sleeve, inspection window, and gray body grip area. The label shows the medication name and dosage of 40 mg/0.4 mL.*

FDA Label Image

1 (Avt02 Unbranded 50)

Simlandi (adalimumab-ryvk) Injection 40 mg/0.4 mL kit packaging label showing a single-dose autoinjector for subcutaneous use. The label includes the proprietary and generic names, dosage strength, intended use, and the labeler as Teva Pharmaceuticals USA, Inc. It also identifies included components such as the autoinjector, alcohol prep, and guides.*

FDA Label Image

2 (Avt02 Unbranded 51)

Packaging label for Simlandi (adalimumab-ryvk) Injection, 20 mg/0.2 mL, for subcutaneous use only. The label indicates the kit contains 2 single-dose prefilled syringes and includes usage instructions and warnings. Manufactured by Teva Pharmaceuticals USA, Inc., the label features a syringe illustration and product details such as storage conditions and pharmacist instructions.*

FDA Label Image

3 (Avt02 Unbranded 52)

Simlandi (adalimumab-ryvk) Injection 40 mg/0.4 mL kit packaging label displays the product name, strength, and dosage form as a subcutaneous injection in a kit containing 2 single-dose prefilled syringes. The label includes manufacturer and marketer details (Avotceh USA Inc. and Teva Pharmaceuticals USA), lot and expiration data fields, a syringe illustration, and usage instructions. The labeling emphasizes Rx only status and proper storage instructions.*

FDA Label Image

4 (Avt02 Unbranded 53)

Simlandi (adalimumab-ryvk) Injection 80 mg/0.8 mL kit packaging label by Teva Pharmaceuticals USA, Inc. The label indicates a single-dose prefilled syringe for subcutaneous use, with contents including a dose tray, alcohol preps, quick reference guide, instructions, medication guide, and prescribing information. Storage and usage instructions are provided on the label, alongside manufacturer details and barcode.*

FDA Label Image

1 (Avt02 Unbranded 6)

An instructional illustration labeled 'Figure A' showing a hand placing a rectangular product box into a refrigerator compartment, depicting how to store the medication kit appropriately.*

FDA Label Image

1 (Avt02 Unbranded 7)

An instructional illustration labeled Figure B showing a clock face highlighting a time range of 15 to 30 minutes in red. The illustration likely indicates a waiting or observation period for medication administration or processing time.*

FDA Label Image

Figure C (Avt02 Unbranded 8)

An instructional diagram labeled Figure C showing the components of the Adalimumab-ryvk kit, including a syringe with cap and a pen device. The syringe has a visible expiration date and lot number section marked as YYYY/MM/DD and YYYYMMDD, respectively. The pen contains a visual dose indicator window with dots and arrows.*

FDA Label Image

Figure D (Avt02 Unbranded 9)

An instructional illustration labeled Figure D shows components of a kit for Adalimumab-ryvk, including a prefilled syringe with orange cap, an alcohol swab packet, a cotton ball, and a red sharps disposal container with a yellow lid and opening.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.